Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.

CMS BALANCE Model GLP-1: Who Qualifies, What It Costs, and What Happens Next

Published: March 25, 2026 · Last updated: May 2, 2026

The CMS BALANCE Model GLP-1 program is CMS's two-step effort to expand access to GLP-1 medications for obesity under Medicaid and Medicare Part D. Medicare has long been prohibited by law from covering drugs when used specifically for weight loss, while state Medicaid coverage of obesity drugs has remained optional. If you have been paying $1,000+ a month out of pocket for Wegovy or Zepbound, or if you gave up entirely because the price was out of reach — this program is what you have been waiting for.

The $50 copay does not count toward your Part D deductible or out-of-pocket cap. Low-income subsidies do not apply during the Bridge. The Bridge runs 18 months (July 2026–December 2027). BALANCE will not launch for Medicare Part D in 2027 — the Bridge is the primary path through end of 2027.

We built this page to be the only resource you need. Everything below — eligibility, cost, timelines, risks, and your options if you cannot wait or do not qualify — comes directly from official CMS guidance and verified policy analysis.

At a Glance: Your Three Paths to Medicare GLP-1 Coverage

There are actually three different pathways to GLP-1 coverage under Medicare right now, and most pages on the internet blur them together. That is why people are confused.

What Is the CMS BALANCE Model GLP-1 Program?

The BALANCE Model — it stands for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth — is a voluntary CMS Innovation Center program designed to test whether expanding access to GLP-1 medications for weight management, paired with lifestyle support, can improve health outcomes for Medicare and Medicaid beneficiaries while controlling costs.

In plain English: CMS is using two legal authorities to create new coverage pathways. The 2026 Medicare GLP-1 Bridge is a separate Section 402 demonstration. BALANCE itself is an Innovation Center model under section 1115A of the Social Security Act. Together, they create a path for Medicare and Medicaid to cover GLP-1 medications for weight loss — a use that has been prohibited since 2003.

Why This Exists

For over two decades, Medicare has been prohibited by law from covering medications when prescribed solely for weight loss. That prohibition was written in 2003, long before GLP-1 medications demonstrated the kind of results that are now reshaping how physicians treat obesity — significant weight reduction, improved cardiovascular markers, better blood sugar control, and improvements across conditions like sleep apnea and kidney disease.

Meanwhile, the cost of GLP-1 medications has put them out of reach for most people without insurance coverage. Wegovy carries a list price around $1,350 per month. Zepbound runs approximately $1,086. For the millions of Medicare and Medicaid beneficiaries living with obesity, those prices made access essentially impossible without separate coverage for a non-weight-loss indication.

The BALANCE Model is CMS's effort to close that gap.

Medicare GLP-1 Bridge vs. BALANCE Model: The Difference That Matters Most

This is where most people get lost. They see a headline that says “Medicare covering GLP-1s at $50 per month” and assume it is one program. It is actually two different programs with different rules, different timelines, and different implications for your coverage.

The Medicare GLP-1 Bridge (July 2026 – December 2027)

The Bridge is an 18-month demonstration that gives eligible Medicare Part D beneficiaries access to GLP-1 weight loss medications at a $50 per month copay. CMS extended it through December 2027 after the BALANCE Model's 80% Part D participation threshold was not met — making the Bridge the primary Medicare weight-loss GLP-1 coverage path through end of 2027.

• Runs from July 1, 2026 through December 31, 2027
• Operates outside of the Part D benefit — completely separate from your normal drug coverage
• Your Part D plan does not need to opt in. CMS administers the Bridge directly through Humana as the central processor (BIN 028918 / PCN MEDDGLP1BR)
• Wegovy (injection and tablets), Zepbound KwikPen (not vials or single-dose pens), and Foundayo are available through the Bridge
• Your doctor submits prior authorization to CMS's central processor, not to your insurance company
• You pay $50 per month at the pharmacy — CMS handles the rest

The BALANCE Model for Medicare Part D (Not Launching in 2027)

BALANCE is the longer-term program — but it will not launch for Medicare Part D in 2027. CMS confirmed the 80% participation threshold was not met. The model is designed to run January 2027–December 2031 once launched, and CMS may revisit participation for future years.

• Runs from January 1, 2027 through December 2031
• Your Part D plan must volunteer to participate. Not all plans will.
• Drug list is broader: Mounjaro, Ozempic, Rybelsus, Wegovy, Zepbound (KwikPen), and potentially orforglipron if it receives FDA approval
• Prior authorization goes through your Part D plan's normal process
• Cost-sharing varies by plan type (more on this below)
• Includes a mandatory lifestyle support program provided free by the drug manufacturer

Medicare GLP-1 Coverage 2026: What Actually Starts in July?

Starting July 1, 2026, the Medicare GLP-1 Bridge goes live nationwide. Every state. Every territory. If you are enrolled in a qualifying Part D plan and you meet the clinical criteria, you are eligible — regardless of whether your specific insurance company has done anything.

Here is how it works in practice:

Do You Qualify? Medicare GLP-1 Bridge Eligibility Criteria

Based on the CMS Bridge FAQ released in March 2026, here are the eligibility requirements translated into plain language.

The Quick Checklist

To qualify for the Medicare GLP-1 Bridge, you need all of the following:

Route 1: BMI of 35 or Higher

If your BMI is 35 or above, you qualify based on BMI alone. No additional diagnosis is required. This is the most straightforward path. For reference: a 5'6“ person weighing 217 pounds has a BMI of approximately 35.

Route 2: BMI of 30 or Higher Plus Specific Conditions

If your BMI is between 30 and 34.9, you qualify if you also have one or more of these conditions:

• Heart failure with preserved ejection fraction (HFpEF)
• Uncontrolled hypertension (blood pressure not adequately managed with current treatment)
• Chronic kidney disease stage 3a or higher (CKD stage 3a+)

Route 3: BMI of 27 or Higher Plus Specific Conditions

If your BMI is between 27 and 29.9, you qualify if you also have one or more of these conditions:

• Prediabetes
• History of heart attack (prior myocardial infarction)
• History of stroke (prior cerebrovascular accident)
• Symptomatic peripheral artery disease (PAD)

Which Plan Types Are Eligible for the Bridge?

Dually eligible beneficiaries (those on both Medicare and Medicaid) can participate in the Bridge if they are enrolled in an eligible Part D plan type and meet the clinical criteria.

Who Qualifies Under the BALANCE Model in 2027?

The 2027 BALANCE criteria for Medicare Part D are similar to the Bridge criteria but slightly broader, because BALANCE covers both weight management and currently covered Part D uses.

BALANCE Eligibility for Weight Management

• BMI 35+ — qualifies on BMI alone
• BMI 30+ with HFpEF, uncontrolled hypertension, CKD stage 3a+, moderate or severe obstructive sleep apnea, or noncirrhotic MASH with moderate-to-advanced fibrosis (F2–F3)
• BMI 27+ with prediabetes, prior MI, prior stroke, or symptomatic PAD

BALANCE Eligibility for Currently Covered Uses

BALANCE also covers GLP-1 medications for uses that Medicare Part D already covers today — like type 2 diabetes, cardiovascular risk reduction, and obstructive sleep apnea. For these uses, the standard Part D coverage criteria apply. People who already qualify may be eligible to receive those products at a lower price in participating plans under BALANCE.

The BALANCE Participation Threshold — And What Happened

CMS required an 80% participation threshold: if Part D plans covering at least 80% of all Part D beneficiaries did not apply to participate, CMS would not launch BALANCE in Medicare for 2027. CMS confirmed as of April 30, 2026 that this threshold was not met. BALANCE will not launch for Medicare Part D in 2027.

In response, CMS extended the Bridge through December 31, 2027, so eligible beneficiaries maintain access at $50/month. Watch for announcements during the fall 2027 Annual Enrollment Period (October 15 – December 7, 2027) about whether BALANCE will launch for Medicare Part D in 2028.

What GLP-1 Drugs Are Included?

Medicare GLP-1 Bridge (2026)

Ozempic, Mounjaro, and Rybelsus are not available through the Bridge. Those may be covered under your Part D plan for other indications (like diabetes), but the Bridge is specifically for weight management.

BALANCE Model (2027)

The full BALANCE drug list is significantly broader. Both Eli Lilly and Novo Nordisk have completed negotiations with CMS and agreed to participate.

How Much Will It Actually Cost?

This is where headlines have created the most confusion. “$50 GLP-1s for Medicare” is technically true but missing critical context.

2026 Bridge Cost: $50 Per Month (With Caveats)

Over 18 months (July 2026 through December 2027), you will pay $900 total for Bridge medications. For context: $900 for 18 months of Wegovy, Zepbound KwikPen, or Foundayo compares to approximately $19,500–$24,300 at full retail pricing for the same period — a reduction of more than 95%.

2027 BALANCE Cost: It Depends on Your Plan Type

• Enhanced alternative plans and EGWPs: Up to $50 per 28–30 day supply during the initial coverage phase
• Basic alternative plans: Up to $125 per 28–30 day supply during the initial coverage phase
• Defined standard plans: Not eligible to participate in BALANCE

The important difference from the Bridge: under BALANCE, your GLP-1 costs do count toward your Part D deductible and $2,100 out-of-pocket cap. And Low-Income Subsidy benefits do apply.

Cost Comparison Table

What Is the Lifestyle Support Program Requirement?

You will see this mentioned in almost every official document about BALANCE, and it raises questions: do I have to join a diet program to get my medication?

Here is what it actually means. Under both the Bridge and the full BALANCE Model, all beneficiaries receiving GLP-1 medications for weight management must be provided access to a lifestyle support program. These programs are provided by the drug manufacturer — not by CMS, not by your insurance company, and not by your doctor. They are provided at no cost to you.

The programs include education on reduced-calorie eating, increasing physical activity, and medication adherence. Think of it as structured support — not a gym membership requirement or a mandatory diet class.

Key Dates: Your CMS BALANCE Model Timeline

Here is every date that matters, in order.

Does Medicare Cover GLP-1 for Prediabetes, Sleep Apnea, Heart Disease, or Diabetes?

Each condition has a different coverage pathway, and getting this wrong could cost you months of delays or unnecessary out-of-pocket spending.

What Could Still Stop You From Getting Coverage

We have been giving you the good news. Here is the honest risk picture — because you deserve to make decisions based on the full truth, not headlines.

What About Medicaid Under BALANCE?

The BALANCE Model covers both Medicare and Medicaid, but the Medicaid pathway has its own rules and timeline.

What If You Cannot Wait — or Do Not Qualify?

The Medicare GLP-1 Bridge does not start until July 2026. BALANCE does not start until 2027. Some people do not meet the BMI criteria. Some people's states will not participate. Some people are not on Medicare or Medicaid at all. If any of that describes you, you still have options worth exploring.

FDA-Approved GLP-1s Through a Telehealth Provider

If you have employer insurance, VA coverage, or another plan that covers GLP-1s, telehealth platforms like Ro can help you navigate coverage for medications like Wegovy or Zepbound. Ro offers physician-supervised care, dose management, and insurance navigation tools — though Ro does not coordinate coverage for government insurance programs like Medicare or Medicaid. For cash-pay patients, Ro connects eligible users with manufacturer discount programs.

Compounded GLP-1 Medications for Cash-Pay Patients

For people paying entirely out of pocket — including Medicare beneficiaries who cannot use manufacturer copay cards under federal law — compounded GLP-1 medications through a telehealth provider can be significantly more affordable than brand-name retail pricing. MEDVi is a straightforward option starting at $179 for the first month, with no contracts or membership fees, and includes physician oversight and care team access.

An important distinction: compounded GLP-1 medications are not FDA-approved as finished drug products. They are prepared by licensed, regulated compounding pharmacies and prescribed by licensed physicians — but they have not gone through the same approval process as brand-name medications like Wegovy. If having an FDA-approved product matters most to you, the Bridge (starting July 2026) or a brand-name pathway through insurance is a better fit.

Step by Step: How to Prepare for the Medicare GLP-1 Bridge

If you think you qualify for the Bridge, here is your action plan between now and July 2026. Each step builds on the one before it.

How We Verified This Page

Every factual claim on this page is sourced from official CMS guidance or verified policy analysis. We do not speculate, and we do not fill in blanks with assumptions.

Primary sources used:

• CMS BALANCE Model official page — program overview, eligibility, timeline, FAQ
• CMS Medicare GLP-1 Bridge FAQ — Bridge-specific eligibility criteria, cost mechanics, operational details, plan type eligibility (updated March 9, 2026)
• CMS BALANCE Model RFA (manufacturer) — model design elements, negotiation framework
• KFF: What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid — independent policy analysis, 80% threshold, LIS implications, transition risks
• KFF Quick Take: What Medicare's Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries
• CMS Press Release: CMS Launches Voluntary Model — official announcement, December 23, 2025

Frequently Asked Questions

Still Not Sure Which GLP-1 Program Is Right for You?

We built this page to be the most complete, plainest-English guide to the CMS BALANCE Model anywhere on the internet. But we also know that everyone's situation is different. Your BMI, your diagnoses, your insurance plan, your state, your budget, your timeline — all of those variables affect which path makes sense for you.

Whether you are preparing for the Medicare GLP-1 Bridge in July, exploring BALANCE for 2027, or looking for affordable access right now — the right program depends on where you stand today.